DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
REBOXETINE MESYLATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
REBOXETINE MESYLATE
×
Maximum Phase:
2
First Approval:
None
UNII:
L94J81YNNY
Molecule Type:
Small molecule
Molecular Formula:
C20H27NO6S
Molecular Weight:
409.5
AlogP:
3.19
PSA:
39.72
HBD:
1.0
HBA:
#RotB:
6.0
Source:
BEDORADRINE SULFATE
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive; Asthma; Status Asthmaticus
Beta-2 adrenergic receptor agonist
BEDORADRINE SULFATE
×
Maximum Phase:
2
First Approval:
None
UNII:
P875C0DV2V
Molecule Type:
Small molecule
Molecular Formula:
C48H66N4O14S
Molecular Weight:
955.14
AlogP:
1.57
PSA:
102.26
HBD:
4.0
HBA:
#RotB:
9.0
Source:
ALECSAT
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
ALECSAT
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALBITIAZOLIUM BROMIDE
2
Small molecule
Investigational
Unknown
Unknown
Malaria
Unknown
ALBITIAZOLIUM BROMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
3AC0AJ4ILP
Molecule Type:
Small molecule
Molecular Formula:
C24H42Br2N2O2S2
Molecular Weight:
614.55
AlogP:
4.67
PSA:
48.22
HBD:
2.0
HBA:
#RotB:
17.0
Source:
SUCRALOSE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
SUCRALOSE
×
Maximum Phase:
2
First Approval:
None
UNII:
96K6UQ3ZD4
Molecule Type:
Small molecule
Molecular Formula:
C12H19Cl3O8
Molecular Weight:
397.64
AlogP:
-1.66
PSA:
128.84
HBD:
5.0
HBA:
#RotB:
5.0
Source:
AZD-1236
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis; Pulmonary Disease, Chronic Obstructive
Matrix metalloproteinase 12 inhibitor
AZD-1236
×
Maximum Phase:
2
First Approval:
None
UNII:
B4OQY51WZS
Molecule Type:
Small molecule
Molecular Formula:
C15H19ClN4O5S
Molecular Weight:
402.86
AlogP:
0.51
PSA:
117.7
HBD:
2.0
HBA:
#RotB:
5.0
Source:
INSULIN TREGOPIL
2
Protein
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetes Mellitus
Unknown
INSULIN TREGOPIL
×
Maximum Phase:
2
First Approval:
None
UNII:
3UYC0OZ5ON
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
F-652
2
Protein
Investigational
Unknown
Unknown
Unknown
Unknown
F-652
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Protein
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NETOGLITAZONE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Peroxisome proliferator-activated receptor gamma modulator
NETOGLITAZONE
×
Maximum Phase:
2
First Approval:
None
UNII:
QOV2JZ647A
Molecule Type:
Small molecule
Molecular Formula:
C21H16FNO3S
Molecular Weight:
381.43
AlogP:
4.45
PSA:
55.4
HBD:
1.0
HBA:
#RotB:
5.0
Source:
AFABICIN
2
Small molecule
Investigational
Unknown
Unknown
Infections
Enoyl-[acyl-carrier-protein] reductase [NADPH] inhibitor
AFABICIN
×
Maximum Phase:
2
First Approval:
None
UNII:
DMM8663H2R
Molecule Type:
Small molecule
Molecular Formula:
C23H24N3O7P
Molecular Weight:
485.43
AlogP:
3.15
PSA:
133.41
HBD:
2.0
HBA:
#RotB:
7.0
Source:
ASCRINVACUMAB
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms; Neoplasms; Carcinoma, Hepatocellular; Mesothelioma
Serine/threonine-protein kinase receptor R3 inhibitor
ASCRINVACUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
716FQ5REVO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-582949
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Psoriasis; Vascular Diseases
MAP kinase p38 alpha inhibitor
BMS-582949
×
Maximum Phase:
2
First Approval:
None
UNII:
CR743OME9E
Molecule Type:
Small molecule
Molecular Formula:
C22H26N6O2
Molecular Weight:
406.49
AlogP:
3.12
PSA:
100.42
HBD:
3.0
HBA:
#RotB:
7.0
Source:
GEMCABENE
2
Small molecule
Investigational
Unknown
Unknown
Hypercholesterolemia; Lipid Metabolism Disorders; Non-alcoholic Fatty Liver Disease
Unknown
GEMCABENE
×
Maximum Phase:
2
First Approval:
None
UNII:
B96UX1DDKS
Molecule Type:
Small molecule
Molecular Formula:
C16H30O5
Molecular Weight:
302.41
AlogP:
3.57
PSA:
83.83
HBD:
2.0
HBA:
#RotB:
12.0
Source:
MILK THISTLE
2
Unknown
Investigational
Unknown
Unknown
Colonic Neoplasms; HIV Infections; Diabetic Nephropathies; Gambling; Hepatitis C, Chronic; Renal Insufficiency, Chronic; Trichotillomania
Unknown
MILK THISTLE
×
Maximum Phase:
2
First Approval:
None
UNII:
U946SH95EE
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ASP8273
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ASP8273
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BMS-986020
2
Small molecule
Investigational
Unknown
Unknown
Idiopathic Pulmonary Fibrosis; Scleroderma, Localized
Lysophosphatidic acid receptor Edg-2 antagonist
BMS-986020
×
Maximum Phase:
2
First Approval:
None
UNII:
38CTP01B4L
Molecule Type:
Small molecule
Molecular Formula:
C29H26N2O5
Molecular Weight:
482.54
AlogP:
6.74
PSA:
101.66
HBD:
2.0
HBA:
#RotB:
7.0
Source:
RECOMBINANT CD40-LIGAND
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
RECOMBINANT CD40-LIGAND
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LYSERGIDE
2
Small molecule
Investigational
Unknown
Unknown
Anxiety; Depressive Disorder, Major; Pain
Unknown
LYSERGIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
8NA5SWF92O
Molecule Type:
Small molecule
Molecular Formula:
C20H25N3O
Molecular Weight:
323.44
AlogP:
2.91
PSA:
39.34
HBD:
1.0
HBA:
#RotB:
3.0
Source:
RIPASUDIL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
RIPASUDIL
×
Maximum Phase:
2
First Approval:
None
UNII:
11978226XX
Molecule Type:
Small molecule
Molecular Formula:
C15H18FN3O2S
Molecular Weight:
323.39
AlogP:
1.75
PSA:
62.3
HBD:
1.0
HBA:
#RotB:
2.0
Source:
TAPRENEPAG ISOPROPYL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Prostanoid EP2 receptor agonist
TAPRENEPAG ISOPROPYL
×
Maximum Phase:
2
First Approval:
None
UNII:
81LDP7XIYG
Molecule Type:
Small molecule
Molecular Formula:
C27H28N4O5S
Molecular Weight:
520.61
AlogP:
3.99
PSA:
103.62
HBD:
0.0
HBA:
#RotB:
11.0
Source:
LOMIBUVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase negative allosteric modulator
LOMIBUVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
37L2LF4A2D
Molecule Type:
Small molecule
Molecular Formula:
C25H35NO4S
Molecular Weight:
445.63
AlogP:
5.31
PSA:
77.84
HBD:
2.0
HBA:
#RotB:
4.0
Source:
GR205171
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GR205171
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CBP
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
CBP
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAMATASVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Nonstructural protein 5A inhibitor
SAMATASVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
21P699C5FC
Molecule Type:
Small molecule
Molecular Formula:
C47H48N8O6S2
Molecular Weight:
885.08
AlogP:
9.37
PSA:
174.64
HBD:
4.0
HBA:
#RotB:
11.0
Source:
AZD2423
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia; Pain; Pulmonary Disease, Chronic Obstructive
C-C chemokine receptor type 2 antagonist
AZD2423
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ARTEMISIA VULGARIS
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
ARTEMISIA VULGARIS
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
C16G2
2
Unknown
Investigational
Unknown
Unknown
Dental Caries
Cell membrane disrupting agent
C16G2
×
Maximum Phase:
2
First Approval:
None
UNII:
B04Z1JB2HS
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UPADACITINIB TARTRATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
UPADACITINIB TARTRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
7KCW9IQM02
Molecule Type:
Small molecule
Molecular Formula:
C21H33F3N6O11
Molecular Weight:
602.52
AlogP:
2.91
PSA:
78.32
HBD:
2.0
HBA:
#RotB:
3.0
Source:
REMTOLUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Psoriatic; Arthritis, Rheumatoid
Interleukin 17A inhibitor
REMTOLUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1V8WRH3RVX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
JNJ-26489112
2
Small molecule
Investigational
Unknown
Unknown
Epilepsy, Reflex
Unknown
JNJ-26489112
×
Maximum Phase:
2
First Approval:
None
UNII:
G1TI012DLT
Molecule Type:
Small molecule
Molecular Formula:
C9H11ClN2O4S
Molecular Weight:
278.72
AlogP:
0.27
PSA:
90.65
HBD:
2.0
HBA:
#RotB:
3.0
Source:
KHK-4083
2
Unknown
Investigational
Unknown
Unknown
Colitis, Ulcerative; Dermatitis, Atopic
Tumor necrosis factor receptor superfamily member 4 antagonist
KHK-4083
×
Maximum Phase:
2
First Approval:
None
UNII:
G770V925KP
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NADECNEMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
NADECNEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LIDORESTAT
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies
Unknown
LIDORESTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
R3734K0M7L
Molecule Type:
Small molecule
Molecular Formula:
C18H11F3N2O2S
Molecular Weight:
376.36
AlogP:
4.34
PSA:
55.12
HBD:
1.0
HBA:
#RotB:
4.0
Source:
GPX-100
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GPX-100
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DOLASTATIN 10
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DOLASTATIN 10
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
196
197
198
199
200
201
202
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA